Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

iodine I 131 MIP-1095

A radioconjugate composed of MIP-1095, a urea-based ligand for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA), radiolabeled with iodine I 131 (I131), with potential antineoplastic activity. Upon administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells. PSMA is a transmembrane glycoprotein that is highly expressed by malignant prostate epithelial cells and certain other tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:(131) I-MIP-1095
131I-MIP-1095
I-131 MIP-1095
MIP-1095 I-131
Chemical structure:((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(131)I]iodophenyl)ureido)pentyl)ureido)pentanedioic acid
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search